[Capecitabine-induced hyperpigmentation].
Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy.
Servicio de Dermatología, Hospital Universitario Reina Sofía, Córdoba, España.
C
C
Vázquez-Bayo
A L
AL
Rodríguez-Bujaldón
R
R
Jiménez-Puya
M
M
Galán-Gutiérrez
J C
JC
Moreno-Giménez
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000601:surgery; D000069287:Capecitabine; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005533:Foot Dermatoses / Q000209:etiology*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced*; D015409:Mastectomy, Radical; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil